FORM	4
-------------	---

(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person – Young David]	2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner				
(Last) (First) (Mi C/O PROCESSA PHARMACEUTICAL INC., 7380 COCA COLA DRIVE, SUIT	LS,	3. Date of Earliest Transaction (Month/Day/Year) 12/31/2021					XOfficer (give title below) Other (specify below) Chief Executive Officer					
(Street) HANOVER, MD 21076		4. If Amendment, Date Original Filed(Month/Day/Year) 01/04/2022						6. Individual or Joint/Group Filing(Check Applicable Line)Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(City) (State) ((Zip)	Table I - Non-Derivative Securities Acqu						ired, Disposed of, or Beneficially Owned				
(Instr. 3) Date	nth/Day/Year)	Execution Date, if	(Instr. 8)		(A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or		of (D)		Direct (D) or Indirect (I)	Beneficial Ownership		
			Code	V	Amount	(D)	Price		(Instr. 4)			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts calls warrants ontions convertible securities)

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Number 6. Date Exercisable		7. Title and Amount		8. Price of			11. Nature		
Derivative	Conversion	Date	Execution Date, if	Transact	ion	of and Expiration Date		of Underlying 1		Derivative	Derivative	Ownership	of Indirect		
Security	or Exercise	(Month/Day/Year)	any	Code		Derivat	ive	(Month/Day	/Year)	Securities Sec		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)		Securiti			(Instr. 3 and 4) (Inst		(Instr. 5)	Beneficially	Derivative	Ownership	
Ì.	Derivative		· · · ·			Acquire	d	· · · · · · · · · · · · · · · · · · ·				Owned	Security:	(Instr. 4)	
	Security					(A) or					Direct (D)				
						Dispose	d						0	or Indirect	
						of (D)							Transaction(s)		
						(Instr. 3	. 4.							(Instr. 4)	
						and 5)	, .,						((
											Amount				
								Date	Expiration Date		or				
								Exercisable	Date		Number				
									Duite		of				
				Code	V	(A)	(D)				Shares				
Restricted															
		10/21/2021				(700		(1)	(1)	Common	(700	¢ 0	22 = 700 (2)	D	
Stock	\$ 0	12/31/2021		Α		6,722		<u></u>	11	Stock	6,722	\$ 0	22,780 ⁽²⁾	D	
Units										SISUR					

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Young David C/O PROCESSA PHARMACEUTICALS, INC. 7380 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076	Х	Х	Chief Executive Officer					

Signatures

/s/ David Young by Michael B. Kirwan, as Attorney-in-Fact	01/06/2022
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.
- (2) This Amendment is being filed to correct the balance in Box 9 this should have reflected a cumulative balance.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.